KORU Medical director awarded 3,571 KRMD shares

KORU Medical Systems director Matin Shahriar received a grant of common stock as part of equity compensation.

Rhea-AI Filing Summary

KORU Medical Systems director Matin Shahriar received a grant of common stock as part of equity compensation. On the reported date, Shahriar acquired 3,571 shares of KORU Medical Systems, Inc. common stock at $4.20 per share in a non-derivative award transaction.

Following this grant, Shahriar directly holds 101,144 shares of KORU Medical Systems common stock. This filing reflects a stock award rather than an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 3,571 shares

Grant/Award 1 txn

Insider Matin Shahriar

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	3,571	$4.20	$15K

Holdings After Transaction: Common Stock — 101,144 shares (Direct)

Key Figures

Shares granted: 3,571 shares Grant price: $4.20 per share Shares owned after grant: 101,144 shares

3 metrics

Shares granted 3,571 shares Non-derivative stock award to director Matin Shahriar

Grant price $4.20 per share Value per share for the 3,571-share stock grant

Shares owned after grant 101,144 shares Direct holdings after the reported transaction

Key Terms

Grant, award, or other acquisition, non-derivative, Common Stock

3 terms

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

non-derivative financial

"transaction_type: non-derivative"

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did KRMD director Matin Shahriar report on this Form 4?

Director Matin Shahriar reported receiving a stock grant of 3,571 shares of KORU Medical Systems common stock. The shares were awarded at $4.20 per share as a non-derivative equity compensation transaction, not an open-market trade.

Was the KRMD insider transaction a stock purchase or a compensation grant?

The KRMD insider transaction was a compensation grant, not an open-market purchase. Transaction code A denotes a “Grant, award, or other acquisition,” meaning the 3,571 shares were awarded to director Matin Shahriar rather than bought in the market.

How many KRMD shares does Matin Shahriar hold after this reported grant?

After receiving the 3,571-share award, Matin Shahriar directly holds 101,144 shares of KORU Medical Systems common stock. This total reflects his direct beneficial ownership immediately following the reported non-derivative equity grant transaction.

What price per share was used for the KRMD stock grant to Matin Shahriar?

The KRMD stock grant to Matin Shahriar used a value of $4.20 per share. This figure represents the price per share reported for the 3,571 awarded shares of KORU Medical Systems, Inc. common stock in the non-derivative transaction.

Does the KRMD Form 4 for Matin Shahriar involve any derivative securities or options?

No, the reported KRMD transaction involves non-derivative common stock only. The filing shows a direct grant of 3,571 shares, and the derivative summary section is empty, indicating no options, warrants, or other derivative securities in this specific report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/01/2026 - 05:20 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Matin Shahriar

(Last) (First) (Middle)

C/O KORU MEDICAL SYSTEMS, INC.

100 CORPORATE DRIVE

(Street)

MAHWAH NEW JERSEY 07430

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KORU Medical Systems, Inc. [ KRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		A		3,571	A	$4.2	101,144	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

The filing of this statement shall not be construed as an admission (a) that the person filing this statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this statement, or (b) that this statement is legally required to be filed by such person. Power of Attorney has been previously filed.

	/s/ Thomas Adams - Attorney-in-Fact	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)